Sai Life Sciences Ltd (SAILIFE)
₹1,557.50
Mkt cap
₹33,093 Cr
P/E ratio
90.00
P/B
13.31
Div yield
0.00%
ROE
15.40%
ROCE
19.60%
EPS (TTM)
₹17.31
Book value
₹117
52W range
784–1,697
Sector
Healthcare
Price history
Previous close
Incorporated in 1999, Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industries [1]
NSE SAILIFEBSE 544306
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−8.22% from high₹1,558
₹784+98.70% from low₹1,697
Current
₹1,557.50
Prev close
₹1,495.70
Day
+4.13%
Price performance
1D
+4.33%
1W
+11.84%
1M
+0.04%
3M
+18.65%
6M
+47.90%
1Y
+74.91%
YTD
+68.98%
Financials
Revenue, profit & margin
P/E ratio
90.0×
SAILIFE is 164% above the sector median of 34.0×
SAILIFE90.0×
Sector median34.0×
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 384 | 439 | 280 | 396 | 440 | 580 | 496 | 537 | 556 | 602 | 554 | |
| Expenses | 287 | 315 | 254 | 293 | 320 | 422 | 375 | 392 | 369 | 426 | 406 | |
| Operating Profit | 96 | 125 | 26 | 102 | 120 | 158 | 121 | 146 | 188 | 177 | 148 | |
| OPM % | 25% | 28% | 9% | 26% | 27% | 27% | 24% | 27% | 34% | 29% | 27% | |
| Other Income | 11 | 3 | 8 | 10 | 9 | 10 | 10 | 15 | 0 | 16 | 4 | |
| Interest | 23 | 21 | 21 | 21 | 23 | 11 | 12 | 9 | 10 | 8 | 8 | |
| Depreciation | 31 | 31 | 31 | 36 | 34 | 37 | 38 | 40 | 44 | 45 | 46 | |
| Profit before tax | 53 | 76 | -18 | 55 | 72 | 119 | 81 | 112 | 134 | 139 | 98 | |
| Tax % | 25% | 26% | -25% | 25% | 25% | 26% | 25% | 25% | 25% | 25% | 25% | |
| Net Profit | 40 | 56 | -14 | 42 | 54 | 88 | 60 | 84 | 100 | 104 | 73 | |
| EPS in Rs | 2.59 | 4.24 | 2.90 | 4.00 | 4.75 | 4.92 | 3.45 | |||||
| Raw PDF |
Earnings
Results dates & reactionsNext results
5 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.15% · closed higher next day 5 of last 7
| Q3FY25 | Q4FY25† | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|
| Broadcast | 7 Feb '25◦ | 14 May '25◦ | 7 Aug '25◦ | 6 Nov '25◦ | 5 Feb '26◦ | 14 May '26◦ | 6 Aug '26◦ |
| Earnings day | −4.43% | +4.45% | +4.59% | −5.08% | +4.80% | −1.94% | −3.42% |
| +1 day | −9.67% | +4.11% | +12.85% | −1.65% | +10.21% | +0.04% | +0.90% |
| +5 days | −11.10% | +2.05% | +13.72% | −5.46% | +12.83% | +0.12% | +2.58% |
| +15 days | −3.74% | +0.56% | +4.28% | −4.11% | +23.11% | +7.38% | +5.06% |
| +30 days | −1.49% | +4.63% | +12.72% | −0.51% | +21.87% | +10.95% | +13.76% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202634.50%Promoter
Promoters34.50%0.03
FIIs19.91%0.26
DIIs32.32%0.39
Public13.25%0.14
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Sai Life | ₹1,557.50 | 89.99 | 33,093 | 0.00% | 73 | +21.22% | 554 | +11.66% | 19.65% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports2
Concall transcripts20
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 19 Oct - Earnings Call details for unaudited financial results for the second quarter and half year ended 30th September 2026.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 12 Oct - Allotment of 54,500 Equity Shares having Face Value of Rs. 1/- each, as per Companies ESOP PlanCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 5 Oct - Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended 30th September 2026.Board Meeting Intimation for Unaudited Financial Results Of Q-2 (FY 2026-27) 1 Oct - Board meeting on 5 November 2026 to approve Q2 and half-year unaudited results; trading window closed till 7 November.Closure of Trading Window 28 Sep